- Home
- VERO vs TOVX Comparison
VERO vs TOVX Comparison
Compare VERO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERO
- TOVX
- Stock Information
- Founded
- VERO N/A
- TOVX 2001
- Country
- VERO Canada
- TOVX United States
- Employees
- VERO N/A
- TOVX N/A
- Industry
- VERO Medical/Dental Instruments
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- VERO Health Care
- TOVX Health Care
- Exchange
- VERO Nasdaq
- TOVX Nasdaq
- Market Cap
- VERO 4.5M
- TOVX 4.5M
- IPO Year
- VERO N/A
- TOVX 2006
- Fundamental
- Price
- VERO $2.40
- TOVX $0.42
- Analyst Decision
- VERO
- TOVX Hold
- Analyst Count
- VERO 0
- TOVX 1
- Target Price
- VERO N/A
- TOVX N/A
- AVG Volume (30 Days)
- VERO 31.4K
- TOVX 1.0M
- Earning Date
- VERO 08-14-2025
- TOVX 08-11-2025
- Dividend Yield
- VERO N/A
- TOVX N/A
- EPS Growth
- VERO N/A
- TOVX N/A
- EPS
- VERO N/A
- TOVX N/A
- Revenue
- VERO $60,107,000.00
- TOVX N/A
- Revenue This Year
- VERO N/A
- TOVX N/A
- Revenue Next Year
- VERO $7.47
- TOVX N/A
- P/E Ratio
- VERO N/A
- TOVX N/A
- Revenue Growth
- VERO N/A
- TOVX N/A
- 52 Week Low
- VERO $2.10
- TOVX $0.37
- 52 Week High
- VERO $14.50
- TOVX $7.15
- Technical
- Relative Strength Index (RSI)
- VERO 45.57
- TOVX 43.60
- Support Level
- VERO $2.25
- TOVX $0.45
- Resistance Level
- VERO $2.49
- TOVX $0.54
- Average True Range (ATR)
- VERO 0.11
- TOVX 0.05
- MACD
- VERO -0.01
- TOVX 0.00
- Stochastic Oscillator
- VERO 31.98
- TOVX 27.94
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.